Assess whether pediatric studies are necessary or waivable (6b10c7)

Situation

The desk packet is phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy. Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Pediatric studies are necessary / Waivable using phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Labeling negotiator can defend Pediatric studies are necessary from phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend Pediatric studies are necessary from phase-3 protocol with endpoint-sensitivity issues; Waivable is what the extract actually supports after a CRL citing manufacturing, not efficacy.
• A CRL citing manufacturing, not efficacy never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close pediatric studies are necessary.
• Two facts in phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy conflict for labeling negotiator; hold this CMC and Development Pathways file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a CRL citing manufacturing, not efficacy and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.